Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month High After Analyst Upgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price reached a new 52-week high during trading on Thursday after Barclays raised their price target on the stock from $1,050.00 to $1,200.00. Barclays currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as high as $1,085.00 and last traded at $1,082.00, with a volume of 45622 shares traded. The stock had previously closed at $1,071.12.

Other research analysts have also recently issued reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Monday, June 17th. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Evercore ISI began coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,038.77.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The disclosure for this sale can be found here. Insiders sold a total of 65,074 shares of company stock valued at $64,546,123 over the last three months. 7.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. West Paces Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $28,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. MCF Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the last quarter. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

The company has a 50 day simple moving average of $1,013.72 and a 200 day simple moving average of $964.22. The company has a market capitalization of $121.21 billion, a price-to-earnings ratio of 32.50, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.